Rigel Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RIGL research report →
About the company
Rigel Pharmaceuticals, Inc. , a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
- CEO
- Raul R. Rodriguez
- IPO
- 2000
- Employees
- 174
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $716.40M
- P/E
- 1.93
- P/S
- 2.39
- P/B
- 1.78
- EV/EBITDA
- 5.62
- Div Yield
- 0.00%
- Gross Margin
- 93.39%
- Op Margin
- 41.56%
- Net Margin
- 121.51%
- ROE
- 147.03%
- ROIC
- 27.96%
- Revenue
- $294.28M · 64.15%
- Net Income
- $367.02M · 1999.08%
- EPS
- $20.40 · 1960.61%
- Op Income
- $125.47M
- FCF YoY
- 143.46%
- 52W High
- $52.24
- 52W Low
- $18.24
- 50D MA
- $31.33
- 200D MA
- $34.02
- Beta
- 1.13
- Avg Volume
- 396.94K
Get TickerSpark's AI analysis on RIGL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 22, 26 | Ali-Jackson Kamil | sell | 2,500 |
| Jun 17, 26 | Furey Raymond J. | other | 7,394 |
| Jun 17, 26 | RODRIGUEZ RAUL R | other | 31,700 |
| Jun 17, 26 | Rojkjaer Lisa | other | 9,375 |
| Jun 17, 26 | Rojkjaer Lisa | other | 7,394 |
| Jun 17, 26 | Santos David A | other | 7,394 |
| Jun 17, 26 | Schorno Dean L | other | 7,394 |
| Jun 1, 26 | Schorno Dean L | other | 2,181 |
| Jun 1, 26 | Schorno Dean L | other | 928 |
| Jun 1, 26 | Schorno Dean L | other | 1,200 |
Our RIGL coverage
Recent articles, reports, and earnings notes.
No research on RIGL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RIGL report →Similar companies
Peers in the same neighborhood.